How are transplant options evolving for patients with ALL?

During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the ALL Hub spoke to Aaron Logan, UCSF, San Francisco, US. We asked, How are transplant options evolving for patients with acute lymphoblastic leukemia (ALL)?

Logan begins by highlighting that increased use of alternative donors, especially haploid donors, has allowed transplants for people who wouldn't have had one previously. He goes on to outline improvements in criteria to identify patients that would benefit from transplant e.g. MRD positivity or high risk genetic lesions. Finally, he discusses advances in bridging therapies such as lintuzumab and the evolution of CAR T-cell therapy.